Skip to main content

Sign up for our newsletter.

Quality journalism. Progressive values. Direct to your inbox.

For Immediate Release


Phone: (202) 588-1000

Press Release

Report: Johnson & Johnson Fails to Deliver Any Contracted Doses to COVAX in October, While Providing 12 Million to Wealthy Countries


Johnson & Johnson prioritized COVID-19 vaccine doses to wealthy countries, including the U.S. and European Union while failing to meet even the most modest delivery targets for COVAX, the global initiative to supply low-income countries, a new Public Citizen report found.

Last month, COVAX expected a delivery of four million doses from the 200 million doses it contracted with Johnson & Johnson, according to the report. However, COVAX received none of the initial contracted doses that month, while rich countries with largely vaccinated populations, including the U.S. and members of the EU, received nearly 12 million doses from the manufacturer. COVAX only started receiving its first contracted doses the week of Nov. 15. These instances highlight vaccine manufacturers prioritizing their contracts with wealthy nations over COVAX and low-income countries that are in desperate need of vaccines.

“Vaccine makers are picking wealthy countries over poor ones, making it harder to achieve global vaccination and end the pandemic,” said Peter Maybarduk, director of Public Citizen’s Access to Medicines program. “Johnson & Johnson let COVAX down; failing to deliver even a single contracted dose for months.”

On Monday, Johnson & Johnson announced that Europe would donate up to 100 million of the company’s doses to COVAX “through the remainder of this year and into early 2022.” But Public Citizen’s report also found that Johnson & Johnson restricted the EU in its initial contract from making donations to COVAX intended for upper middle-income countries, including Botswana, Libya and South Africa.

“Johnson & Johnson cannot be allowed to call the shots on who gets access,” said Zain Rizvi, research director in Public Citizen’s Access to Medicines program. “Wealthy governments can rein in Johnson & Johnson and help vaccinate the world quickly.”

Public Citizen urged the U.S. and EU to require that Johnson & Johnson and other manufacturers prioritize deliveries to COVAX and other developing countries, and called on the U.S. to use the Defense Production Act to require manufacturers to share vaccine recipes to increase production globally.


Public Citizen is a nonprofit consumer advocacy organization that champions the public interest in the halls of power. We defend democracy, resist corporate power and work to ensure that government works for the people – not for big corporations. Founded in 1971, we now have 500,000 members and supporters throughout the country.

Sanders Calls on Biden to Slash 'Outrageous' Medicare Premium Hike

"It would be absolutely unacceptable to force 57 million senior citizens to pay $11.50 more a month in Medicare premiums" due to Big Pharma's greed, the Vermont senator said.

Jake Johnson ·

'Biden's Oily Christmas': Climate Campaigners Call Out Public Lands Giveaways

"His Interior Department has plowed forward with new oil and gas lease sales that wreck our public lands and exacerbate climate change—all while enriching the CEOs of big oil corporations."

Jessica Corbett ·

'Indefensible': Outrage Over Man in Wheelchair Fatally Shot in the Back by Arizona Cop

Richard Lee Richards was shot nine times in the back and side by a Tucson officer, who has since been fired, earlier this week.

Brett Wilkins ·

'Global Empire of the US Christian Right': Dark Money Fuels Attacks on Abortion Rights Worldwide

The findings of a new investigation, said one observer, "further demonstrate the growing trend of religious extremists forging cross-border alliances" to gut abortion rights.

Jake Johnson ·

Public Health Experts Slam 'Grossly Inadequate,' Industry-Friendly Covid Test Reimbursement Scheme

"We need this administration to be courageous," said one physician. "This is not it at all."

Julia Conley ·

Support our work.

We are independent, non-profit, advertising-free and 100% reader supported.

Subscribe to our newsletter.

Quality journalism. Progressive values.
Direct to your inbox.

Subscribe to our Newsletter.

Common Dreams, Inc. Founded 1997. Registered 501(c3) Non-Profit | Privacy Policy
Common Dreams Logo